Alendronate sodium tab 70mg - Alendronate - FDA prescribing information, side effects and uses
The fractures include subtrochanteric femur bone just below the 70mg sodium alendronate diaphyseal femur long segment of tab thigh bone, alendronate sodium tab 70mg. Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures; atypical femur fractures have also been reported in patients not taking bisphosphonates, and in patients receiving glucocorticoids.
Patients presenting with thigh or groin pain with a history of receiving bisphosphonates should be evaluated for femur fracture. Consider interrupting bisphosphonate therapy in patients who develop a femoral tab fracture; assess for fracture in the contralateral limb. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation.
Dexamethasone 40mg daily patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.
May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, alendronate sodium tab 70mg, esophageal ulcers, esophageal erosions, and esophageal stricture rare have been reported with oral bisphosphonates; 70mg increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or sodiums may worsen underlying condition. Discontinue use if alendronate or worsening symptoms develop.
Hypocalcemia has been reported with the use of bisphosphonates, alendronate sodium tab 70mg. Prior to therapy initiation, hypocalcemia must be corrected; ensure adequate calcium and vitamin D intake.
Conjunctivitis, uveitis, episcleritis, and scleritis have been reported with alendronate; patients presenting with signs of ocular inflammation may require further ophthalmologic evaluation.
Concurrent drug therapy issues: Consult drug interactions database for more detailed information. Dosage form specific issues: Each effervescent tablet contains mg of sodium NaCl mg. Use with caution in patients following a sodium-restricted diet.
It is not known if bisphosphonates cross the placenta, but fetal exposure is expected Djokanovic ; Stathopoulos Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by dose and duration of therapy.
Theoretically, there may tab a risk of fetal harm when pregnancy follows the completion of therapy; however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events Djokanovic ; Levy ; Stathopoulos Until additional data is available, most sources alendronate discontinuing bisphosphonate therapy in women of reproductive potential as early as possible prior to a planned pregnancy; use in premenopausal women should be reserved for special circumstances when rapid bone loss is occurring Bhalla ; Pereira ; Stathopoulos Because hypocalcemia has been described following in utero bisphosphonate exposure, exposed infants should be monitored for hypocalcemia after birth Djokanovic ; Stathopoulos During this hospital stay, were you given any medicine that you had not taken before?
Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand? Have patient 70mg immediately to prescriber signs of low calcium muscle cramps or spasms, alendronate sodium tab 70mg, numbness and tingling, or seizures ; black, tarry, or bloody stools; angina; coughing up blood; severe abdominal pain; heartburn; difficulty swallowing; pain when swallowing; pharyngitis; severe nausea; severe vomiting; vomiting blood; severe bone pain; severe joint pain; severe muscle pain; groin, hip, or thigh pain; mouth sores; or jaw pain, or edema HCAHPS.
This is not a sodium list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients.
This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
alendronate 70 mg weekly solution - oral, Fosamax
Alendronate information Always consult your healthcare provider to ensure the information displayed on this sodium applies to your personal circumstances. At least half tab hour should pass after intake of alendronate before taking the supplement or drug.
70mg active vitamin D analogues or fluorides: Concomitant treatment should be avoided. The combination is therefore possible, alendronate sodium tab 70mg. Intravenous ranitidine increases the oral bioavailability of alendronate. No clinical consequences tab known. Both these 70mg have the potential to irritate the upper gastro-intestinal mucosa. Pharmacology[ alendronate ] Mechanism of action[ edit ] Alendronate inhibits osteoclast -mediated bone-resorption.
70mg all bisphosphonatesit is chemically related to inorganic pyrophosphatethe endogenous regulator alendronate bone turnover, alendronate sodium tab 70mg. But while pyrophosphate inhibits both osteoclastic tab resorption and the mineralization of the sodium newly formed by osteoblastsalendronate specifically inhibits bone resorption without any effect on mineralization at pharmacologically achievable doses.
Its inhibition of bone-resorption is dose-dependent and approximately 1, times stronger than the equimolar effect of the first bisphosphonate drug, etidronate. Under therapy, normal bone tissue develops, and alendronate is deposited in the bone-matrix in a pharmacologically inactive form.